763113-22-0 Olaparib - Watson International Ltd
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
Olaparib | AZD-2281 | CAS#763113-22-0 | MedKoo
PharmaWiki - Olaparib
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
HemOnc.org | A Hematology Oncology Wiki
PARP inhibitors: Synthetic lethality in the clinic | Science
Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian ca
Targeting dePARylation selectively suppresses DNA repair–defective and PARP inhibitor–resistant malignancies | Science Advances
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
Supplementary appendix
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
Olaparib - Wikipedia
Olaparib | C24H23FN4O3 | CID 23725625 - PubChem
令癌莎- Wikiwand
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. - Abstract - Europe PMC
Olaparib CAS 763113-22-0 Watson International Limited
HemOnc.org | A Hematology Oncology Wiki
Olaparib: Cos'è, A Cosa Serve, Quando si Assume
Tankyrase inhibitors as antitumor agents: a patent update (2013 – 2020)
